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Objectives: Whilst the cost-effectiveness of everolimus + exemestane (EVE+EXE) 
versus placebo + exemestane (PBO+EXE) in patients with ER+ HER2- metastatic 
breast cancer has been demonstrated elsewhere, this is the first analysis to assess 
the implications for health spending at a population level. MethOds: The model 
uses a cumulative cohort approach, allowing incident patients to enter the model 
each year over a five-year period. The incident population was based on several 
factors: (i) the female population aged > 15 years; (ii) the proportion of those women 
with advanced invasive breast cancer; (iii) the proportion who are post-menopausal; 
(iv) the proportion who are hormone receptor positive; (v) the proportion who are 
HER2-; (vi) the proportion with asymptomatic visceral disease, and (vii) the propor-
tion for whom hormonal therapy is appropriate. Finally, the cohort was filtered 
to show those who had previously relapsed or progressed on NSAI. ‘Per patient’ 
treatment and adverse event costs were generated based on treatment-specific 
progression-free survival curves, and multiplied by the number of patients expected 
to receive each treatment according to market share data and likely uptake rates. 
An incremental analysis was performed, where two scenarios were compared: (i) a 
world without EVE+EXE, and (ii) a world with EVE+EXE. Results: It is expected that 
a total of 1,052 patients will be eligible to receive EVE+EXE over a five-year period. 
In a ‘world without EVE+EXE’, the total five year cost was estimated as £1,652,904. 
Assuming an annual uptake rate of 10%, in a ‘world with EVE+EXE’ the total cost 
over the same period was expected to be £2,271,606. Therefore, the incremental cost 
associated with the introduction of EVE+EXE in England and Wales is £618,702 over 
five years. cOnclusiOns: EVE+EXE was associated with modest increased health 
care costs but has, separately, been demonstrated to lead to incremental health 
benefits compared with other treatments.
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Objectives: There is a dearth of published health economic evidence on stem cell 
(SC) mobilization that can be leveraged effectively for transplant center decision 
making. Our objective was to develop representative budget impact models (BIM) for 
key decision makers to estimate the total financial impact of adopting plerixafor for 
SC mobilization patients undergoing autologous peripheral stem cell transplanta-
tion (ASCT) for multiple myeloma and lymphoma. The BIMs were developed for EU5 
(France, Germany, Italy, Spain, UK) and United States (US). MethOds: Prior to BIM 
development, in-depth interviews were conducted in EU5 (n= 33) and US (n= 20), to 
determine the most influential decison maker(s) for choosing a mobilization regi-
men. The choice of inputs and outputs that are critical for the adoption of plerixafor 
at the hospital level, were determined. Additionally, the BIM was developed using 
inputs from published literature and market research. Results: Primary research 
revealed that the center director and treating physician are the most influential 
decision makers, while hospital administrators, transplant coordinators, pharmacy 
directors, and apheresis directors have a more limited role. There was consensus 
on inputs critical for assessment: clinical (drug/regimen utilization, apheresis days, 
and success/failure rates) and economic (mobilization costs; drug costs; apheresis 
cost and hospitalization costs). Model outputs include: first mobilization success 
and total mobilization budget impact. Interviews with clinical experts, and primary 
literature review determined that the relevant mobilization regimen comparators 
for the models are Granulocyte-Colony Stimulating Factor (G-CSF) alone, G-CSF and 
plerixafor, G-CSF and chemotherapy mobilization with cyclophosphamide and the 
triple regimen G-CSF, chemotherapy mobilization and plerixafor. cOnclusiOns: 
Conducting primary interviews with key stakeholders and using the latest clinical 
practice information for critical inputs/outputs is essential for developing a repre-
sentative model that is applicable to decison makers.
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Objectives: In the Basque Country (Spain), mammographies have been done in bien-
nial basis to women in their fifties and sixties since 1996. The main objective of this 
project was the evaluation of the impact of the Screening program in terms of costs 
and health in the Basque women population since 1996. MethOds: A discrete event 
simulation model was built to represent the natural history of breast cancer in women 
invited to the breast cancer screening program in the Basque Country. The disease 
progress was described in three main states (healthy, preclinical and clinical) in the 
model. We assumed all women would be diagnosed at the beginning of the clinical 
stage unless it had been diagnosed previously through the screening program. The data 
collected among the 15 years when the screening program was held allowed model’s 
validation. In order to compare the economic impact of these scenarios mammography 
and treatment costs – depending on the diseasestage at diagnosis – were included. The 
health impact assessment was based on quality adjusted life expectancy of cancer 
patients. Results: Since the screening program started working, 8,925 cancers were 
detected among 313,475 women who attended the screening which represents the 76% 
of the invited ones. 60% of the diagnosed cancers were detected through the screening 
program. All the mammographies carried out during the evaluated years costed 46 
million Euros. Each cancer detected in the screened scenario costs 29,581.06€ , in the 
based treatment effect for denosumab versus ZA to estimate the denosumab SRE 
rate. Total number of SREs, total SRE management medical cost, BTA drug cost, 
and total cost were calculated. The impact of denosumab per-member-per-month 
(PMPM) at increasing utilization rates was assessed by comparing to a scenario 
without denosumab, i.e., all patients received ZA and reported. Additionally, 
impact of annual increase in denosumab use was conducted. Results: A total 
of 63 PrCa patients with BM received BTA. In the scenario where all eligible patients 
receiving ZA, an annual total number of SREs was 120. An annual denosumab use 
of 20%, 35% or 45% resulted in 4.2%, 7.4%, and 9.5% reduction in total SREs and 
5.3%, 9.3%, and 11.9% reduction in medical costs of managing SREs, compared to 
all patients receiving ZA. The drug cost was partially offset by the reductions in 
the medical cost and the increase in total cost was minimal (1.2%-2.7%). The PMPM 
ranged $0.002-$0.005. Consecutive-year analysis showed $0.001 increase in PMPM 
with 10% denosumab utilization increase. cOnclusiOns: Due to superior efficacy 
of denosumab versus ZA in SRE prevention in PrCa patients with BM, increased 
denosumab use results in medical cost reduction in a US MCO. Overall, denosumab 
provides additional clinical value with limited budget impact.
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Objectives: Ipilimumab is the first drug to be licensed in Italy for the treatment 
of advanced melanoma in adults who have received prior therapy. This study 
aims to estimate the budget impact of ipilimumab in patients who live in the 
Veneto Region. MethOds: Our analysis was performed from the perspective 
of the Italian health care system. Two scenarios were analyzed: one with the 
optimization of vials and the other without. Only drug acquisition costs (meas-
ured in euro) were considered into the analysis. All costs were referred to year 
2013. Results: Based on the incidence and mortality rates of the last three 
years, a total of 80 adult patients were assumed to be elegible for the treatment 
in the Veneto Region. The cost per mg of ipilimumab was € 53,70: one 10 ml vial 
contains 50 mg of ipilimumab and one 40 ml vial contains 200 mg of ipilimumab. 
The recommended induction regimen is 3 mg/kg administered intravenously 
every 3 weeks for a total of 4 doses. The costs per patient of one year’s therapy 
with ipilimumab ranged from € 45.108 with vial optimization (considering 4-5 
patients infused at the same time - average weight 70 kg) to € 53.700 without. 
The Veneto Region identified a single center for the preparation/administration 
of treatment to minimize drug waste and to reduce the yearly treatment cost 
per patient, with a saving of € 8.592 per patient/year. Applied to whole elegible 
patients (average weight 70-75 kg), it allows to obtain savings up to € 430.000-
690.000 per year. cOnclusiOns: High prices for new cancer drugs are a growing 
concern to payers, given the large number of cancer drugs in development and 
the limited health care resources. Vial optimization may be an useful strategy 
to decrease waste, maximizing the use of health care resources and ensuring 
that eligible patients are treated.
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Objectives: To compare the budget requirements of utilizing epoetin alfa Hexal vs. 
darbepoetin alfa in the German health care system MethOds: Anemia is a com-
mon side effect observed in patients receiving myelosuppressive chemotherapy. The 
purpose of this pharmacoeconomic analysis was to evaluate the cost-effectiveness 
of the short-acting biosimilar ESAs epoetin-alfa Hexal (EA) 30,000 or 40,000 IU weekly 
(QW) versus long-acting erythropoiesis-stimulating agent (ESA) darbepoetin alfa 
(DA) 150 mcg weekly (QW) and 500 mcg once every 3 weeks (Q3W) for the treatment 
of CIA. A budget impact model was constructed employing a payer perspective, per 
patient plus 5 year time horizon. The treatment period considered was based on 12 
weeks and was aligned with routine chemotherapy regimen administration. Model 
inputs included: medical treatment, outcomes, and health care service utilization 
from published clinical studies and summary of product characteristics recom-
mendation. Effectiveness of therapeutic alternatives was determined by comparing 
hemoglobin maintenance rates. Initial treatment with biosimilar epoetin α 30,000 
IU or 40,000 IU per week has been shown to produce a similar Hb response. Costs 
included only drug acquisition costs and reflect 2013 data. The analysis was per-
formed from the perspective of the German health care system. Results: The 
average expected pharmaceutical costs per patient were € 4,843 for DA Q3W, € 4,383 
for DA QW and € 2,944 for EA 30,000IU QW, € 3,946 for EA 40,000IU QW. Cost-savings 
associated utilizing with utilizing Epoetin Alfa Hexal 30-40,000 are 11-49% to DA 
QW and were 23-64% relative to DA 3QW. cOnclusiOns: In the treatment of CIA 
among cancer patients in Germany, epoetin alfa Hexal is projected to provide more 
efficient use of health care resources compared to alternative treatment strategies 
with darbepoetin alfa.
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